Detailed Instructions: In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
See one example below:
Problem: SECTION 1. LIABILITY OF BUSINESS ENTITIES PROVIDING USE OF FACILITIES
TO NONPROFIT ORGANIZATIONS.

(a) Definitions.--In this section:
(1) Business entity.--The term ''business entity'' means a
firm, corporation, association, partnership, consortium, joint
venture, or other form of enterprise.
(2) Facility.--The term ''facility'' means any real
property, including any building, improvement, or appurtenance.
(3) Gross negligence.--The term ''gross negligence'' means
voluntary and conscious conduct by a person with knowledge (at
the time of the conduct) that the conduct is likely to be
harmful to the health or well-being of another person.
(4) Intentional misconduct.--The term ''intentional
misconduct'' means conduct by a person with knowledge (at the
time of the conduct) that the conduct is harmful to the health
or well-being of another person.
(5) Nonprofit organization.--The term ''nonprofit
organization'' means--
(A) any organization described in section 501(c)(3)
of the Internal Revenue Code of 1986 and exempt from
tax under section 501(a) of such Code; or
(B) any not-for-profit organization organized and
conducted for public benefit and operated primarily for
charitable, civic, educational, religious, welfare, or
health purposes.
(6) State.--The term ''State'' means each of the several
States, the District of Columbia, the Commonwealth of Puerto
Rico, the Virgin Islands, Guam, American Samoa, the Northern
Mariana Islands, any other territory or possession of the
United States, or any political subdivision of any such State,
territory, or possession.
(b) Limitation on Liability.--
(1) In general.--Subject to subsection (c), a business
entity shall not be subject to civil liability relating to any
injury or death occurring at a facility of the business entity
in connection with a use of such facility by a nonprofit
organization if--
(A) the use occurs outside of the scope of business
of the business entity;
(B) such injury or death occurs during a period
that such facility is used by the nonprofit
organization; and
(C) the business entity authorized the use of such
facility by the nonprofit organization.
(2) Application.--This subsection shall apply--
(A) with respect to civil liability under Federal
and State law; and
(B) regardless of whether a nonprofit organization
pays for the use of a facility.
(c) Exception for Liability.--Subsection (b) shall not apply to an
injury or death that results from an act or omission of a business
entity that constitutes gross negligence or intentional misconduct,
including any misconduct that--
(1) constitutes a crime of violence (as that term is
defined in section 16 of title 18, United States Code) or act
of international terrorism (as that term is defined in section
2331 of title 18) for which the defendant has been convicted in
any court;
(2) constitutes a hate crime (as that term is used in the
Hate Crime Statistics Act (28 U.S.C. 534 note));
(3) involves a sexual offense, as defined by applicable
State law, for which the defendant has been convicted in any
court; or
(4) involves misconduct for which the defendant has been
found to have violated a Federal or State civil rights law.
(d) Superseding Provision.--
(1) In general.--Subject to paragraph (2) and subsection
(e), this Act preempts the laws of any State to the extent that
such laws are inconsistent with this Act, except that this Act
shall not preempt any State law that provides additional
protection from liability for a business entity for an injury
or death with respect to which conditions under subparagraphs
(A) through (C) of subsection (b)(1) apply.
(2) Limitation.--Nothing in this Act shall be construed to
supersede any Federal or State health or safety law.
(e) Election of State Regarding Nonapplicability.--This Act shall
not apply to any civil action in a State court against a business
entity in which all parties are citizens of the State if such State
enacts a statute--
(1) citing the authority of this subsection;
(2) declaring the election of such State that this Act
shall not apply to such civil action in the State; and
(3) containing no other provision.
Solution: Shields a business entity from civil liability relating to any injury or death occurring at a facility of that entity in connection with a use of such facility by a nonprofit organization if: (1) the use occurs outside the scope of business of the business entity; (2) such injury or death occurs during a period that such facility is used by such organization; and (3) the business entity authorized the use of such facility by the organization.
Makes this Act inapplicable to an injury or death that results from an act or omission of a business entity that constitutes gross negligence or intentional misconduct, including misconduct that: (1) constitutes a hate crime or a crime of violence or act of international terrorism for which the defendant has been convicted in any court; or (2) involves a sexual offense for which the defendant has been convicted in any court or misconduct for which the defendant has been found to have violated a Federal or State civil rights law.
Preempts State laws to the extent that such laws are inconsistent with this Act, except State law that provides additional protection from liability. Specifies that this Act shall not be construed to supersede any Federal or State health or safety law.
Makes this Act inapplicable to any civil action in a State court against a business entity in which all parties are citizens of the State if such State, citing this Act's authority and containing no other provision, enacts a statute declaring the State's election that this Act shall not apply to such action in the State.
Explanation: This Bill focuses on shielding business entities from civil liability relating to an injury or death depending on the conditions of injury, hence the generated summary is correct.

Problem: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Right to Try Act''.

SEC. 2. USE OF UNAPPROVED MEDICAL PRODUCTS BY PATIENTS DIAGNOSED WITH A
TERMINAL ILLNESS.

(a) In General.--Notwithstanding the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 301 et seq.), the Controlled Substances Act (21
U.S.C. 801 et seq.), and any other provision of Federal law, the
Federal Government shall not take any action to prohibit or restrict--
(1) the production, manufacture, distribution, prescribing,
or dispensing of an experimental drug, biological product, or
device that--
(A) is intended to treat a patient who has been
diagnosed with a terminal illness; and
(B) is authorized by, and in accordance with, State
law; and
(2) the possession or use of an experimental drug,
biological product, or device--
(A) that is described in subparagraphs (A) and (B)
of paragraph (1); and
(B) for which the patient has received a
certification from the patient's treating physician in
accordance with subsection (b).
(b) Physician Certification.--A certification by the patient's
treating physician referred to in subsection (a)(2)(B) must include
each of the following:
(1) A certification that the physician--
(A) is in good standing with the physician's
certifying organization or board; and
(B) has personally examined the patient.
(2) A certification that there is no reason to conclude the
experimental drug, biological product, or device poses an
unreasonable and significant risk of danger to the patient.
(3) A certification that the patient has been diagnosed
with a terminal disease or condition and does not have any
treatment options that--
(A) are comparable to treatment using the
experimental drug, biological product, or device or
otherwise satisfactory; and
(B) are approved, licensed, or cleared for
commercial distribution under section 505, 510(k), or
515 of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355, 360(k), 360(e)) or section 351 of the
Public Health Service Act (42 U.S.C. 262) and are
available to diagnose, monitor, or treat the patient's
disease or condition.
(4) A certification that the probable risk to the patient
from the experimental drug, biological product, or device is
not greater than the probable risk from the patient's disease
or condition.
(5) A certification that the physician has provided the
patient with a written statement and oral explanation of the
medical treatment to be provided using the experimental drug,
biological product, or device.
(6) An acknowledgement signed by the patient (or the
patient's legal representative) that the physician has provided
the written statement and oral explanation required by
paragraph (5), and has disclosed the following:
(A) That the medical treatment using the
experimental drug, biological product, or device is
experimental or nonconventional.
(B) That the experimental drug, biological product,
or device has not been approved, licensed, or cleared
for commercial distribution under section 505, 510(k),
or 515 of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355, 360(k), 360(e)) or section 351 of the
Public Health Service Act (42 U.S.C. 262) for any
indication.
(C) The material risks generally recognized by a
reasonably prudent physician of the medical treatment's
side effects.
(D) An explanation of the medical treatment,
including the expected frequency and duration of the
treatment.
(c) No Liability or Use of Outcomes.--
(1) No liability.--Notwithstanding any other provision of
law, no liability shall lie against a producer, manufacturer,
distributor, prescriber, dispenser, possessor, or user of an
experimental drug, biological product, or device for the
production, manufacture, distribution, prescribing, dispensing,
possession, or use of an experimental drug, biological product,
or device that is in compliance, with subsection (a).
(2) No use of outcomes.--Notwithstanding any other
provision of law, the outcome of any production, manufacture,
distribution, prescribing, dispensing, possession, or use of an
experimental drug, biological product, or device that was done
in compliance with subsection (a) shall not be used by a
Federal agency reviewing the experimental drug, biological
product, or device to delay or otherwise adversely impact
review or approval of such experimental drug, biological
product, or device.
(d) Rules of Construction.--Nothing in this Act shall be construed
to--
(1) require a manufacturer or other person to make
available any experimental drug, biological product, or device;
or
(2) prohibit a manufacturer or other person from receiving
compensation or recovering costs for the production,
manufacture, distribution, or sale of an experiment drug,
biological product, or device.
(e) Definitions.--In this section:
(1) Biological product.--The term ''biological product''
has the meaning given to such term in section 351 of the Public
Health Service Act (42 U.S.C. 262).
(2) Device; drug.--The terms ''device'' and ''drug'' have
the meanings given to such terms in section 201 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 321).
(3) Experimental drug, biological product, or device.--The
term ''experimental drug, biological product, or device'' means
a drug, biological product, or device that--
(A) has successfully completed a phase 1 clinical
investigation;
(B) remains under investigation in a clinical trial
approved by the Food and Drug Administration; and
(C) is not approved, licensed, or cleared for
commercial distribution under section 505, 510(k), or
515 of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355, 360(k), 360(e)) or section 351 of the
Public Health Service Act (42 U.S.C. 262).
(4) Phase 1 clinical investigation.--The term ''phase 1
clinical investigation'' means a phase 1 clinical
investigation, as described in section 312.21 of title 21, Code
of Federal Regulations (or any successor regulations).
(5) Terminal illness.--The term ''terminal illness'' has
the meaning given to such term in the State law specified in
subsection (a)(1)(B).
Solution:
Right to Try Act This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are authorized by state law and intended to treat terminally ill patients. Patients receiving these treatments must be certified by a physician as having exhausted all other treatment options and as being at greater risk from their medical condition than the treatment. The physician must explain the treatment to the patient, including that the treatment is experimental, and the patient, or the patient's legal representative, must acknowledge the explanation. A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment. The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment. The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration (FDA); and (3) not be approved, licensed, or cleared for sale by the FDA.